Palopegteriparatide, a novel long-acting prodrug of parathyroid hormone (PTH), has been evaluated in randomized controlled trials for chronic hypoparathyroidism (HypoPT). Now, a study has evaluated its effectiveness and safety in a real-world setting involving 92 adults treated at multiple tertiary hospitals. Patients previously treated with recombinant human PTH or conventional therapy received palopegteriparatide for a median of 6.5 months. Following treatment, albumin-adjusted calcium increased from 8.14 to 8.99 mg/dL and magnesium from 1.79 to 1.96 mg/dL.

In contrast, phosphate decreased from 4.74 to 4.02 mg/dL, Ca × P product from 38.27 to 36.04 mg²/dL², and 24-hour urinary calcium from 245.7 to 164.5 mg/24 h. Notably, 58% of patients achieved independence from calcium supplements and alfacalcidol after a median of 30 days. Adverse events were mostly mild and transient. These…